Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
COCP Stock Forecast 2025-2026
$1.51
Current Price
$15.46M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to COCP Price Targets
+562.3%
To High Target of $10.00
+429.8%
To Median Target of $8.00
+297.4%
To Low Target of $6.00
COCP Price Momentum
+1.3%
1 Week Change
-7.4%
1 Month Change
-36.0%
1 Year Change
-25.2%
Year-to-Date Change
-53.7%
From 52W High of $3.26
+34.8%
From 52W Low of $1.12
📊 TOP ANALYST CALLS
Did COCP Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Cocrystal Pharma is one of their latest high-conviction picks.
Latest COCP Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, COCP has a bullish consensus with a median price target of $8.00 (ranging from $6.00 to $10.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $1.51, the median forecast implies a 429.8% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Raghuram Selvaraju at HC Wainwright & Co., projecting a 562.3% upside. Conversely, the most conservative target is provided by Raghuram Selvaraju at HC Wainwright & Co., suggesting a 297.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
COCP Analyst Ratings
2
Buy
0
Hold
0
Sell
COCP Price Target Range
Low
$6.00
Average
$8.00
High
$10.00
Current: $1.51
Latest COCP Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for COCP.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 20, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $6.00 |
| Jan 22, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $7.00 |
| Aug 22, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $7.00 |
| May 14, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Apr 4, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Mar 20, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Jan 3, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $10.00 |
| Dec 4, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $12.00 |
| Oct 4, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $12.00 |
| Aug 15, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $12.00 |
| Aug 11, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $12.00 |
| Jun 2, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $12.00 |
| May 24, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $12.00 |
| Jan 24, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $35.00 |
| Nov 7, 2022 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $42.00 |
| Nov 12, 2020 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $4.50 |
| Jul 8, 2020 | HC Wainwright & Co. | Buy | Initiates | $0.00 | |
| Jun 16, 2020 | Noble Capital Markets | Outperform | Initiates | $0.00 |
Cocrystal Pharma Inc. (COCP) Competitors
The following stocks are similar to Cocrystal Pharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
COCP
Cocrystal Pharma
mkt cap
15.46M
Cocrystal Pharma Inc. (COCP) Financial Data
Cocrystal Pharma Inc. has a market capitalization of $15.46M with a P/E ratio of -0.9x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -106.1%.
Valuation Metrics
Market Cap
$15.46M
Enterprise Value
$9.97M
P/E Ratio
-0.9x
PEG Ratio
-0.7x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+45.0%
Current Ratio
4.6x
Debt/Equity
23.7x
ROE
-106.1%
ROA
-54.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cocrystal Pharma Inc. (COCP) Business Model
About Cocrystal Pharma Inc.
What They Do
Develops antiviral therapeutics for viral infections.
Business Model
Cocrystal Pharma operates by innovating in antiviral drug discovery, utilizing unique structure-based technologies to target viral replication mechanisms. The company generates revenue through the development of antiviral therapeutics aimed at serious and chronic viral infections, focusing on unmet medical needs in the virology sector.
Additional Information
Cocrystal Pharma is positioned to make a significant impact in the pharmaceutical industry, particularly as the demand for effective antiviral solutions increases. Their extensive research and development efforts contribute to addressing high-priority public health threats and enhancing patient outcomes.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
11
CEO
Dr. Sam Lee Ph.D.
Country
United States
IPO Year
2012
Website
www.cocrystalpharma.comCocrystal Pharma Inc. (COCP) Latest News & Analysis
Latest News
Cocrystal Pharma's Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference
1 month ago
Quick Summary
Cocrystal Pharma, Inc. (Nasdaq: COCP) will present its protease inhibitor CDI-988 at the 2025 Military Health System Research Symposium from August 4-7 in Kissimmee, Florida.
Why It Matters
The presentation of CDI-988 at a major health research symposium could enhance Cocrystal Pharma's visibility, attract potential partnerships, and influence stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Cocrystal Pharma to Participate in Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference
1 month ago
Quick Summary
Cocrystal Pharma, Inc. (Nasdaq: COCP) will participate in a fireside chat at the Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference on June 5, 2025, at 12:00 p.m.
Why It Matters
Cocrystal's participation in the equity conference signals potential growth opportunities, attracting interest from investors looking for emerging biotech stocks.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cocrystal Pharma's CC-42344 shows strong antiviral activity against the 2024 Texas H5N1 avian influenza strain, confirmed by recent virology studies, enhancing its potential as a treatment.
Why It Matters
Cocrystal Pharma's CC-42344 shows significant antiviral potential against a dangerous H5N1 strain, indicating future revenue opportunities and enhancing the company's market position.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cocrystal Pharma announced that CDI-988 showed strong antiviral activity against norovirus variants and reported its Q1 2025 financial results and updates on its product pipeline.
Why It Matters
Cocrystal Pharma's CDI-988 shows strong antiviral potential, which could lead to increased market demand and revenue growth, directly impacting stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cocrystal Pharma's drug candidate CDI-988 shows strong binding to GII.17 protease, similar to prior GII.4 strains. A human challenge study is set for 2025 to assess its efficacy against norovirus.
Why It Matters
Cocrystal Pharma's CDI-988 shows promise against norovirus, potentially positioning the company for significant market opportunities and investor interest in its upcoming clinical trials.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cocrystal Pharma, Inc. (Nasdaq: COCP) will have President and co-CEO Sam Lee present a company overview at the LSINW 2025 Conference on April 23, 2025, at 3:00 p.m.
Why It Matters
Cocrystal Pharma's presentation at a prominent conference could highlight its innovations, attract investor interest, and potentially affect stock performance based on market reception and future prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About COCP Stock
What is Cocrystal Pharma Inc.'s (COCP) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Cocrystal Pharma Inc. (COCP) has a median price target of $8.00. The highest price target is $10.00 and the lowest is $6.00.
Is COCP stock a good investment in 2026?
According to current analyst ratings, COCP has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.51. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for COCP stock?
Wall Street analysts predict COCP stock could reach $8.00 in the next 12 months. This represents a 429.8% increase from the current price of $1.51. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cocrystal Pharma Inc.'s business model?
Cocrystal Pharma operates by innovating in antiviral drug discovery, utilizing unique structure-based technologies to target viral replication mechanisms. The company generates revenue through the development of antiviral therapeutics aimed at serious and chronic viral infections, focusing on unmet medical needs in the virology sector.
What is the highest forecasted price for COCP Cocrystal Pharma Inc.?
The highest price target for COCP is $10.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 562.3% increase from the current price of $1.51.
What is the lowest forecasted price for COCP Cocrystal Pharma Inc.?
The lowest price target for COCP is $6.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 297.4% increase from the current price of $1.51.
What is the overall COCP consensus from analysts for Cocrystal Pharma Inc.?
The overall analyst consensus for COCP is bullish. Out of 2 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $8.00.
How accurate are COCP stock price projections?
Stock price projections, including those for Cocrystal Pharma Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 8, 2025 4:30 AM UTC